Sign inJoin waitlistJoin the waitlist

Aram Zabeti

Division Director · University of Cincinnati Medical Center Inc.

Credentials: · · · · · ·

History

Waddell Center for Multiple Sclerosis · University of Cincinnati Medical Center Inc.
Present
University of Cincinnati Medical Center Inc.
Present

Oregon Health & Science University
2012–2013
Neurology
West Virginia University School of Medicine
2008–2012
Doctor of Medicine
1995–1999

Research

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
New England Journal of Medicine · 2018 · 231 citations
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for…
Journal of Multiple Sclerosis · 2022 · 62 citations
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis
Contemporary Clinical Trials · 2016 · 56 citations

Omid Mirmosayyeb
12 papers · 4 as a resident
Ahmed Obeidat
3 papers · 2 as a fellow
Daniel Ontaneda
3 papers
Michael Levy
3 papers
MG
Myla Goldman
3 papers
PR
Pavle Repovic
3 papers
Robert Bermel
3 papers
Rohini Samudralwar
3 papers
Shamik Bhattacharyya
3 papers
Allen Aksamit
2 papers
Andrew Goodman
2 papers
AF
Angela Flores
2 papers

Clinical trials

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2025–2031
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Site PI · Recruiting · Phase 2
University of Utah
2022–2028
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Site PI · Recruiting · Phase 3
National Institute of Allergy and Infectious Diseases (NIAID)
2020–2029